Jazz Pharmaceuticals plc — Director's Dealing 2018

Sep 7, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2018-09-06

Reporting Person: ENRIGHT PATRICK G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-09-06	Ordinary Shares	M	3415	$143.66	Acquired	19884	Direct
2018-09-06	Ordinary Shares	M	3415	$138.08	Acquired	23299	Direct
2018-09-06	Ordinary Shares	M	3300	$135.44	Acquired	26599	Direct
2018-09-06	Ordinary Shares	S	2044	$167.9576	Disposed	24555	Direct
2018-09-06	Ordinary Shares	S	7086	$168.8633	Disposed	17469	Direct
2018-09-06	Ordinary Shares	S	1000	$169.694	Disposed	16469	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-06	Non-Qualified Stock Option (right to buy)	$135.44	M	3300	Disposed	2024-08-06	Ordinary Shares (3300)	Direct
2018-09-06	Non-Qualified Stock Option (right to buy)	$138.08	M	3415	Disposed	2026-08-10	Ordinary Shares (3415)	Direct
2018-09-06	Non-Qualified Stock Option (right to buy)	$143.66	M	3415	Disposed	2027-08-09	Ordinary Shares (3415)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $167.47 to $168.44. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $168.53 to $169.43. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $169.68 to $169.70. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: This non-qualified stock option was granted on August 7, 2014 and vested over a period of one year from August 1, 2014. The options were fully vested as of July 1, 2015.

F6: This non-qualified stock option was granted on August 11, 2016 and vested over a period of one year from September 1, 2016. The options were fully vested as of August 1, 2017.

F7: This non-qualified stock option was granted on August 10, 2017 and vested over a period of one year from September 1, 2017. The options were fully vested as of August 1, 2018.